Abstract
Raw data on the cumulative number of deaths at a country level generally indicate a spatially variable distribution of the incidence of COVID-19 disease. An important issue is to determine whether this spatial pattern is a consequence of environmental heterogeneities, such as the climatic conditions, during the course of the outbreak. Another fundamental issue is to understand the spatial spreading of COVID-19. To address these questions, we consider four candidate epidemiological models with varying complexity in terms of initial conditions, contact rates and non-local transmissions, and we fit them to French mortality data with a mixed probabilistic-ODE approach. Using standard statistical criteria, we select the model with non-local transmission corresponding to a diffusion on the graph of counties that depends on the geographic proximity, with time-dependent contact rate and spatially constant parameters. This original spatially parsimonious model suggests that in a geographically middle size centralized country such as France, once the epidemic is established, the effect of global processes such as restriction policies, sanitary measures and social distancing overwhelms the effect of local factors. Additionally, this modeling approach reveals the latent epidemiological dynamics including the local level of immunity, and allows us to evaluate the role of non-local interactions on the future spread of the disease. In view of its theoretical and numerical simplicity and its ability to accurately track the COVID-19 epidemic curves, the framework we develop here, in particular the non-local model and the associated estimation procedure, is of general interest in studying spatial dynamics of epidemics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by INRAE (MEDIA network) and by the EHESS
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Contact : lionel.roques{at}inrae.fr
Data Availability
All data used in this manuscript are publicly available. French mortality data at the county scale are available at https://www.gouvernement.fr/info-coronavirus/carte-et-donnees